Form D · Pharmaceuticals
Hapten Sciences, Inc.
Memphis, TN · CIK 0001526465
Offering snapshot reported Aug 10, 2021 · SEC filing
- Reported sold
- Yet to sell Offering amount: $3M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 10, 2021 | Initial | Yet to sell | No comparison | Not reported | SEC filing |
| Oct 31, 2019 | Initial | $885,980 | No comparison | 4 | SEC filing |
| Sep 20, 2018 | Amendment | $1,587,768 | $955,042vs Feb 26, 2018 | 5 | SEC filing |
| Feb 26, 2018 | Amendment | $632,726 | $524,526vs Feb 22, 2018 | 3 | SEC filing |
| Feb 22, 2018 | Initial | $108,200 | No comparison | 1 | SEC filing |
| Feb 14, 2017 | Initial | $1,200,000 | No comparison | 8 | SEC filing |
| Jan 12, 2016 | Amendment | $1,225,000 | $1,000,000vs Sep 9, 2015 | 6 | SEC filing |
| Sep 9, 2015 | Initial | $225,000 | No comparison | 4 | SEC filing |
| Apr 16, 2015 | Initial | $250,000 | No comparison | 7 | SEC filing |
| Feb 5, 2015 | Amendment | $625,000 | $150,000vs Jan 2, 2014 | 7 | SEC filing |
| Feb 5, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 2, 2014 | Amendment | $475,000 | No comparison | 5 | SEC filing |
| Feb 20, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jul 21, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-409422
Source: Form D, filed Aug 10, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen L. Bandak | Director |
| Raymond J. Hage | Director, Executive |
| Gary Prosterman | Director, Executive |
| Gary Stevenson | Director |
| Joseph Zakrzewski | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
40 S. Main, Suite 2300
Memphis, TN, 38103
Memphis, TN, 38103